VRN-07 is under clinical development by ORIC Pharmaceuticals and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VRN-07’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VRN-07 overview
VRN-07 is under development for the treatment of solid tumors including non-small cell lung cancer and HER2 positive breast cancer. The therapeutic candidate is administered through oral route. The drug candidate development is based on voronoi kinase platform technology. The drug candidate act by targeting the epidermal growth factor receptor (EGFR) and HER2 with Exon 20 insertions.
See Also:
ORIC Pharmaceuticals overview
ORIC Pharmaceuticals (ORIC Pharmaceuticals) is clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers. The company provides pipeline products such as ORIC-114, ORIC-944, PLK4 and research publications. Its lead drug candidate ORIC-533, is a selective small molecule antagonist of the glucocorticoid receptor (GR), implicated in resistance to various treatment modalities such as chemotherapy, immunotherapy and anti-hormonal therapy across a broad range of cell lines and tumor types. ORIC Pharmaceuticals is headquartered in South San Francisco, California, the US.
For a complete picture of VRN-07’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
